email@example.com to be connected to a study site. Don’t wait! Remember…Research is the
Key to Your Cure!
An oral investigational drug has been developed with the potential to increase sunlight duration and tolerance in
individuals with EPP. This phase II clinical trial is needed to understand if the investigational drug works and to
ensure that it is safe. The study duration is 24 weeks including follow-up. You must be age 18-70 to participate
and have a confirmed diagnosis of EPP. All travel is included and will be arranged by a concierge service.
"Remember...Research is the key to YOUR cure!"
Each Step Toward Finding an Effective Treatment is Important!
The APF is launching a new campaign to request Priority Review
* That there is an unmet medical need for a treatment for EPP
* That living with EPP is a tremendous burden
* How living with EPP affects your quality of life
Scott Gottlieb, M.D.
U.S. Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
Dear FDA Commissioner:
American Porphyria Foundation
4915 St. Elmo Avenue, Suite 105
Bethesda, Maryland 20814
All letters must be signed.
Please send letters today or ASAP! Time is of the Essence!